As of Friday close, Day One Biopharmaceuticals Inc.’s (NASDAQ:DAWN) stock was up $0.14, moving up 1.02 percent to $13.92. The average number of shares traded per day over the past five days has been 670,340 shares. 3 times new highs have been achieved over the past 5 days, with a $0.47 gain in that time frame. In the last twenty days, the average volume was 623,820, while in the previous 50 days, it was 1,003,012.
Since last month, DAWN stock rose 17.47%. Shares of the company fell to $11.44 on 07/20/23, the lowest level in the past month. A 52-week high of $26.72 was reached on 01/09/23 after having rallying from a 52-week low of $10.84. Since the beginning of this year, DAWN’s stock price has dropped by -35.32% or -$7.60, and marked a new high 2 times. However, the stock has declined by -47.90% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
DAWN stock investors should be aware that Day One Biopharmaceuticals Inc. (DAWN) stock had its last reported insider trading activity 2 days ago on Aug 17. Bender Jeremy, the Chief Executive Officer of the company, disposed of 2,996 shares for $13.86 on Aug 17. It resulted in a $41,525 divestment by the insider. York Charles N II sold 922 shares at an average price of $13.86 on Aug 17. The insider now owns 267,501 shares following the transaction. On Aug 17, Head of Research and Developme Blackman Samuel C. sold 668 shares at $13.86 apiece. The transaction was valued at $9,258.
Financial Health
In the three months ended June 29, Day One Biopharmaceuticals Inc.’s quick ratio stood at 18.30, while its current ratio was 18.30, showing that the company is able to pay off its debt. Based on annual data, DAWN earned -$4.75 million in gross profit and brought in $146.91 million in revenue.
According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. While analysts expected Day One Biopharmaceuticals Inc. to report -$0.61 quarterly earnings, the actual figure was -$0.61 per share. During the quarter, the company generated -$49.16 million in EBITDA. The liabilities of Day One Biopharmaceuticals Inc. were 24.7 million at the end of its most recent quarter ended June 29, and its total debt was $0.62 million. The value of shareholders’ equity is $86.97 million.
Technical Picture
This quick technical analysis looks at Day One Biopharmaceuticals Inc.’s (DAWN) price momentum. With a historical volatility rate of 32.86%, the RSI 9-day stood at 67.45% on 18 August.
With respect to its five-day moving average, the current Day One Biopharmaceuticals Inc. price is up by +3.49% percent or $0.47. At present, DAWN shares trade +15.04% above its 20-day simple moving average and +5.45% percent above its 100-day simple moving average. However, the stock is currently trading approximately -3.40% below its SMA50 and -34.15% below its SMA200.
Stochastic coefficient K was 78.54% and Stochastic coefficient D was 79.30%, while ATR was 0.68. Given the Stochastic reading of 83.88% for the 14-day period, the RSI (14) reading has been calculated as 63.19%. As of today, the MACD Oscillator reading stands at 0.21, while the 14-day reading stands at 0.44.
Analyst Ratings
Day One Biopharmaceuticals Inc. downgraded its rating on Day One Biopharmaceuticals Inc. (NASDAQ: DAWN) to an Underperform in a note to investors on April 25, 2023. The analysts firm previously had a Buy rating on the stock.
